An efficient cell selection method is crucial to delivering a consistent autologous therapy product when the starting material received from severely ill patients is highly variable. While a variety of technologies are being adopted in the industry, there are very few GMP options, and many lack the flexibility for multiple passes, and flexibility in reagent selection. In addition, the currently available technologies are often applied in combination with manufacturing platforms that are manual, semi-automated and lacking commercial viability.
During this webinar, our experts will share insights on obtaining highly purified cells using magnetically active cell selection in a flexible, closed manufacturing system. In addition, we will learn about transitioning manual cell therapy production to automated processes that are scalable to meet clinical and commercial demands.